U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT06855095) titled 'Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial' on Oct. 25, 2023.
Brief Summary: According to current guidelines, patients have to withhalt long-acting somatostatin analogues (LA-SSA) for 4-6 weeks prior to every 177Lutetium-DOTATATE administration. The primary objective of the study is to investigate the effect of LA-SSA on the absorbed dose in tumor lesions during PRRT.
Study Start Date: June 25, 2024
Study Type: INTERVENTIONAL
Condition:
Neuroendocrine Tumors
Neuroendocrine Tumor Grade 1
Neuroendocrine Tumor Grade 2
Neuroendocrine Neoplasm
Intervention:
DRUG...